NCT00268385 2026-03-18
Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas
National Cancer Institute (NCI)
Phase 1 Active not recruiting
Clinical Trials
17 trialsNCT02152982 2026-03-18
Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
National Cancer Institute (NCI)
Phase 2/3 Active not recruiting
NCT03478462 2026-03-18
CLOVER-2
Cellectar Biosciences, Inc.
Phase 1 Active not recruiting
NCT04817254 2026-03-18
Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT03115333 2026-03-02
DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma
Eastern Cooperative Oncology Group
Phase NA Active not recruiting
NCT02455557 2026-02-25
SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
Roswell Park Cancer Institute
Phase 2 Active not recruiting
NCT05095376 2026-02-17
Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma
NRG Oncology
Phase 3 Active not recruiting
NCT04216329 2026-01-23
Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
National Institutes of Health Clinical Center (CC)
Phase 1 Active not recruiting
NCT05091866 2026-01-07
Natural Progesterone for the Treatment of Recurrent Glioblastoma
Emory University
Phase EARLY_PHASE1 Active not recruiting
NCT02192359 2025-11-14
Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas
City of Hope Medical Center
Phase 1 Active not recruiting
NCT02062827 2025-10-02
M032-HSV-1
University of Alabama at Birmingham
Phase 1 Active not recruiting
NCT02337686 2025-08-15
Pembrolizumab in Treating Patients With Recurrent Glioblastoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT06614855 2025-08-06
A Phase IB 2 Dose Trial of IRS-1 HSV C134 (IND 17296) Administered Intratumorally in Patients With Recurrent Malignant Glioma
University of Alabama at Birmingham
Phase 1 Active not recruiting
NCT04528680 2025-07-31
SC9/ABX
Northwestern University
Phase 1/2 Active not recruiting
NCT03197506 2025-04-06
Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma
Mayo Clinic
Phase 2 Active not recruiting
NCT01903330 2025-03-05
ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme
Epitopoietic Research Corporation
Phase 2 Active not recruiting
NCT00102648 2024-10-17
Lonafarnib and Temozolomide in Treating Patients with Glioblastoma Multiforme That is Recurrent or Did Not Respond to Previous Treatment with Temozolomide
M.D. Anderson Cancer Center
Phase 1 Active not recruiting